Progesterone for the prevention of preterm birth
Record ID 32011001468
English
Authors' objectives:
Progesterone, in the form of intramuscular injections, vaginal suppositories, vaginal gel, or oral capsules, is used beginning at approximately the start of the second trimester of pregnancy in women with an asymptomatic pregnancy but 1 risk factors for preterm birth (e.g., history of preterm
birth or preterm labor, incompetent cervix, uterine anomaly, multiple gestations, etc.) or beginning shortly after premature rupture of membranes or arrested preterm labor in women who have experienced these symptoms of potential preterm birth. Progesterone is continued until reaching a
gestational age of 34 to 37 weeks or delivery with the goal of prolonging gestation and preventing preterm birth and associated infant morbidity and mortality.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=6791
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Pregnancy
- Premature Birth
- Progesterone
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2011 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.